Disease · MONDO_0006712
corneal edema
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. corneal edema. Diseases, record MONDO_0006712. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006712
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Corneal edema (disorder), Corneal edema NOS (disorder), Corneal edema, unspecified, Corneal oedema, Corneal oedema [Ambiguous], Unspecified corneal edema (disorder), cornea edema
- Open Targets
Drugs10
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SODIUM CHLORIDE | CHEMBL1200574 | Small molecule | Approval | DailyMed | 5 | 3 | 1 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BRIMONIDINE TARTRATE | CHEMBL1200389 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TIMOLOL MALEATE | CHEMBL1200870 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TRIAMCINOLONE | CHEMBL1451 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NETARSUDIL | CHEMBL4594250 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| Y-27632 | CHEMBL559147 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RIPASUDIL | CHEMBL3426621 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| KETOROLAC TROMETHAMINE | CHEMBL1201124 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TOBRAMYCIN | CHEMBL1747 | Small molecule | Unknown | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
Targets10
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| ROCK1 | Rho-associated protein kinase | 2 | Rho-associated protein kinase inhibitor | Phase 2 | https://conductscience.org/library/genes/6093 | Drugs and targets |
| ROCK2 | Rho-associated protein kinase | 2 | Rho-associated protein kinase inhibitor | Phase 2 | https://conductscience.org/library/genes/9475 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 3 | https://conductscience.org/library/genes/152 | Drugs and targets |
| ADRB1 | Beta-1 adrenergic receptor | 1 | Beta-1 adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/153 | Drugs and targets |
| ADRB2 | Beta-2 adrenergic receptor | 1 | Beta-2 adrenergic receptor antagonist | Phase 3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 1 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5743 | Drugs and targets |
Trials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06041256 | A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1) | Phase 1/2 | 97 | 2025-12-17 | Corneal Edema, Corneal Endothelial Dysfunction | Y-27632 | Its record names the disease | ClinicalTrials.gov |
| NCT04498169 | A Phase 2 Study Evaluating the Safety and Efficacy of Netarsudil Ophthalmic Solution in Patients With Corneal Edema Due to Fuchs Corneal Dystrophy | Phase 2 | 40 | 2022-09-01 | Corneal Edema | NETARSUDIL | Its record names the disease | ClinicalTrials.gov |
| NCT00800423 | Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema | Phase 3 | 150 | Corneal Edema, Visual Acuity | BRIMONIDINE TARTRATE, TIMOLOL MALEATE | Its record names the disease | ClinicalTrials.gov | |
| NCT01103401 | Ketorolac Plus Tobramycin/Dexamethasone Versus Tobramycin/Dexamethasone After Uneventful Phacoemulsification Surgery | Not applicable | 145 | Cataract | DEXAMETHASONE, KETOROLAC TROMETHAMINE, TOBRAMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00992355 | Tobramycin-Dexamethasone Versus Tobramycin-Dexamethasone Plus Ketorolac After Phacoemulsification Surgery | Not applicable | 97 | Cataract | DEXAMETHASONE, KETOROLAC TROMETHAMINE, TOBRAMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05271058 | Effect of Intracameral Steroids During Phacoemulsification on the Cornea | Phase 3 | 69 | Corneal Edema | DEXAMETHASONE, TRIAMCINOLONE | Its record names the disease | ClinicalTrials.gov | |
| NCT02660151 | Study of Using the Hyper-CL™ Lens (Hyper Osmotic Contact Lens) in Subjects Suffering From Corneal Edema | Not applicable | 68 | CORNEAL EDEMA | SODIUM CHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT05636579 | Study to Assess Safety and Tolerability of Multiple Doses of EO2002 | Phase 1 | 12 | Corneal Edema, Corneal Endothelial Dystrophy, Endothelial Dysfunction, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Bullous Keratopathy, Pseudophakic Bullous Keratopathy, Corneal Edema Pseudophakic | RIPASUDIL | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Once Daily Netarsudil Ophthalmic Solution vs Twice Daily Netarsudil Ophthalmic Solution: deaths from any cause | 0 of 20 | 0 of 20 | 40 | NCT04498169 | Trial comparisons |
| Once Daily Netarsudil Ophthalmic Solution vs Twice Daily Netarsudil Ophthalmic Solution: serious adverse events | 0 of 20 | 1 of 20 | 40 | NCT04498169 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006712
GET https://conductscience.org/api/diseases/v1/MONDO_0006712/drugs